Markets /Industrials /LDL Lydall, Inc. LDL Full chart Compare Add to watchlist Set alert Price alert · LDL Alert when the price is Price abovePrice below Price level Set alert All alert types — — Day range unavailable 52-week range unavailable Overview Chart Financials FinancialsValuation & healthEarnings EarningsDividends & splitsAnalysts News Ownership Options More ComparisonSignalsTrend ScoreDiscussionNotesPositionsAlerts News All sources Benzinga only 1 day ago marketbeat.com Editas Medicine Plans Human Trial After Gene Therapy Slashed LDL 90% in Primate Study Editas Medicine NASDAQ: EDIT expects to dose the first patients this year in a Phase I/II study of its lead gene-editing candidate, EDIT-401, as the company focuses its development strategy on in…
